BMD changes up to 3 years following treatment with Zoladex or CMF in pre-/perimenopausal women with early breast cancer participating in the ZEBRA study.

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)S331 - S331
JournalJournal of Bone and Mineral Research
Volume16
Publication statusPublished - 2001

Cite this